The unexpected consequences of generic entry

B-Tier
Journal: Journal of Health Economics
Year: 2019
Volume: 68
Issue: C

Score contribution per author:

0.670 = (α=2.01 / 3 authors) × 1.0x B-tier

α: calibrated so average coauthorship-adjusted count equals average raw count

Abstract

Generic drugs are sold at a fraction of the original brand price. Yet, generic entry typically produces a drop in the quantity market share of the molecule losing exclusivity. This effect is economically and statistically significant for a large dataset covering hundreds of prescription drugs sold in the US during the period 1994Q1–2003Q4. This paper proposes the first systematic analysis of what appears to be a market anomaly.

Technical Details

RePEc Handle
repec:eee:jhecon:v:68:y:2019:i:c:s0167629618305332
Journal Field
Health
Author Count
3
Added to Database
2026-01-25